CMS to reverse reimbursement policy that de-emphasized Avastin
The CMS said it will reverse a policy that restricts the prescription of Genentech's Avastin to promote more expensive eye drug Lucentis, possibly before Jan. 1. Genentech supported the move, which would increase reimbursements to doctors who use Avastin in patients with macular degeneration and save the federal government millions of dollars per year.
Wall Street Journal, The | 10/28
This story published in FDLI SmartBrief on 10/29/2009
More from SmartBrief:
CMS proposes changes to MRI coverage
Tuesday, July 7, 2009
2 Virginia startups look to bring medical products to market
Monday, August 10, 2009
Genentech seeks FDA approval for wider use of Avastin
Tuesday, November 17, 2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|